Satellos Bioscience Inc.
MSCLF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $20 | $9 | $337 | $120 |
| Gross Profit | -$20 | -$9 | -$337 | -$120 |
| % Margin | – | – | – | – |
| R&D Expenses | $20 | $9 | $2,587 | $1,884 |
| G&A Expenses | $8 | $7 | $5,439 | $2,600 |
| SG&A Expenses | $8 | $7 | $5,439 | $2,600 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$20 | -$9 | -$49 | -$84 |
| Operating Expenses | $8 | $7 | $8,379 | $4,540 |
| Operating Income | -$28 | -$15 | -$8,407 | -$4,737 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | -$0 | -$2,910 | -$10,652 |
| Pre-Tax Income | -$28 | -$16 | -$11,317 | -$15,506 |
| Tax Expense | $0 | $0 | $6 | $0 |
| Net Income | -$28 | -$16 | -$11,322 | -$15,506 |
| % Margin | – | – | – | – |
| EPS | -0.24 | -0.18 | -0.32 | -0.64 |
| % Growth | -33.3% | 43.8% | 50% | – |
| EPS Diluted | -0.24 | -0.18 | -0.32 | -0.64 |
| Weighted Avg Shares Out | 115 | 86 | 35,680 | 24,076 |
| Weighted Avg Shares Out Dil | 115 | 86 | 35,680 | 24,076 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $21 | $8 |
| Interest Expense | $0 | $0 | $0 | $985 |
| Depreciation & Amortization | $0 | $0 | $337 | $166 |
| EBITDA | -$28 | -$15 | -$8,070 | -$4,571 |
| % Margin | – | – | – | – |